Mean (SE) baseline scores for responding patients vs. progressing patients with WT KRAS tumours were 0.81 (0.03) vs. 0.72 (0.18), respectively; mean scores in responding vs. progressing patients with MT KRAS tumours were 0.82 (0.05) vs. 0.59 (0.20). The gene discussed is KRAS; the disease is neoplasm.